Friday, July 10, 2026

pharma · Inflammatory Bowel Disease (IBD) · Melanoma · IRON

Disc Medicine

Disc Medicine is a pharma organization headquartered in Watertown, USA. It trades on NYSE under ticker IRON. Primary therapeutic focus areas include Inflammatory Bowel Disease (IBD), Melanoma, Parkinson's disease, Falcip

321 Arsenal St., Suite 101, Watertown, Massachusetts 02472-5710, US HQ
165 Employees
Public company Type
IRON · NYSE Ticker
Company details
Status
Public
HQ
321 Arsenal St., Suite 101, Watertown, Massachusetts 02472-5710, US
Employees
165
Programs
308
Drugs
443
Patents
706
Clinical program

PALEXIA Retard 50 mg tabletten met verlengde afgifte

Approved · small molecule · chronic postoperative pain

PALEXIA Retard 50 mg tabletten met verlengde afgifte for chronic postoperative pain is a Approved program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).

← All Disc Medicine projects Approved small molecule active

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Disc Medicine
Phase
Approved
Modality
small_molecule
Indication
chronic postoperative pain
Status
active
Trials
1